Clinical Trial Update: Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

This is a Phase 1 dose-escalation trial evaluating cabozantinib in combination with Lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cabometyx (cabozantinib)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: University of Utah | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: RECRUITING